Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 1-26 , January 2006

Cell Membrane Microparticles in Blood and Blood Products: Potentially Pathogenic Agents and Diagnostic Markers

References 

  1. Freyssinet JM. Cellular microparticles: What are they bad or good for?. J. Thromb. Haemost. 2003;1:1655–1662
  2. Horstman LL, Ahn YS. Platelet microparticles: A wide-angle perspective. Crit. Rev. Oncol. Hematol. 1999;30:111–142
  3. Horstman LL, Jy W, Jimenez JJ, et al. New horizons in the analysis of circulating cell-derived microparticles. Keio J. Med. 2004;53:210–230
  4. Horstman LL, Jy W, Jimenez JJ, et al. Endothelial microparticles as markers of endothelial dysfunction. Front. Biosci. 2004;9:1118–1135
  5. Morel O, Toti F, Hugel B, et al. Cellular microparticles: A disseminated storage pool of bioactive vascular effectors. Curr. Opin. Hematol. 2004;11:156–164
  6. Nomura S, Fukuhara S. Platelet microparticles. Methods Mol. Biol. 2004;272:269–277
  7. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb. Res. 2003;109:175–180
  8. Nomura S. Function and clinical significance of platelet-derived microparticles. Int. J. Hematol. 2001;74:397–404
  9. Chargaff E, West R. The biological significance of the thromboplastic protein of blood. J. Biol. Chem. 1946;166:189–197
  10. Wolf P. The nature and significance of platelet products in human plasma. Br. J. Haematol. 1967;13:269–288
  11. Mack M, Kleinschmidt A, Bruhl H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. Nat. Med. 2000;6:769–775
  12. Jin M, Drwal G, Bourgeois T, et al. Distinct proteome features of plasma microparticles. Proteomics. 2005;5:1940–1952
  13. Hugel B, Martinez MC, Kunzelmann C, et al. Membrane microparticles: Two sides of the coin. Physiology (Bethesda). 2005;20:22–27
  14. Owens MR. The role of platelet microparticles in hemostasis. Transfus. Med. Rev. 1994;8:37–44
  15. Simak J, Holada K, Vostal JG. Release of annexin V–binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. BMC Cell Biol. 2002;3:1–10
  16. Hamilton KK, Hattori R, Esmon CT, et al. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J. Biol. Chem. 1990;265:3809–3814
  17. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J. Clin. Invest. 1999;104:93–102
  18. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89:1121–1132
  19. Seigneuret M, Devaux PF. ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: Relation to shape changes. Proc. Natl. Acad. Sci. U. S. A. 1984;81:3751–3755
  20. Connor J, Pak CH, Zwaal RF, et al. Bidirectional transbilayer movement of phospholipid analogs in human red blood cells. Evidence for an ATP-dependent and protein-mediated process. J. Biol. Chem. 1992;267:19412–19417
  21. Williamson P, Bevers EM, Smeets EF, et al. Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry. 1995;34:10448–10455
  22. Pasquet JM, Dachary-Prigent J, Nurden AT. Microvesicle release is associated with extensive protein tyrosine dephosphorylation in platelets stimulated by A23187 or a mixture of thrombin and collagen. Biochem. J. 1998;333:591–599(Pt 3)
  23. Simak J, Novak J. Ceramide mediated release of membrane microparticles from endothelial cells is controlled by caspase 1 activity and in contrast to executive apoptotic blebbing is kinase independent. Blood. 2003;102:805a;(abstract)
  24. Nagata S. DNA degradation in development and programmed cell death. Annu. Rev. Immunol. 2005;23:853–875
  25. Mills JC, Stone NL, Erhardt J, et al. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J. Cell. Biol. 1998;140:627–636
  26. Maiese K, Vincent AM. Membrane asymmetry and DNA degradation: Functionally distinct determinants of neuronal programmed cell death. J. Neurosci. Res. 2000;59:568–580
  27. Vanags DM, Porn-Ares MI, Coppola S, et al. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol. Chem. 1996;271:31075–31085
  28. Chong ZZ, Kang JQ, Maiese K. AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9. Exp. Cell Res. 2004;296:196–207
  29. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: An overview and current perspectives. Biochim. Biophys. Acta. 2002;1585:114–125
  30. van Blitterswijk WJ, van der Luit AH, Veldman RJ, et al. Ceramide: Second messenger or modulator of membrane structure and dynamics?. Biochem. J. 2003;369:199–211
  31. Boesen–de Cock JG, Tepper AD, de Vries E, et al. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. J. Biol. Chem. 1999;274:14255–14261
  32. Brenner B, Ferlinz K, Grassme H, et al. Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases. Cell Death Differ. 1998;5:29–37
  33. Grullich C, Sullards MC, Fuks Z, et al. CD95(Fas/APO-1) signals ceramide generation independent of the effector stage of apoptosis. J. Biol. Chem. 2000;275:8650–8656
  34. Wiedmer T, Sims PJ. Participation of protein kinases in complement C5b-9–induced shedding of platelet plasma membrane vesicles. Blood. 1991;78:2880–2886
  35. Yano Y, Kambayashi J, Shiba E, et al. The role of protein phosphorylation and cytoskeletal reorganization in microparticle formation from the platelet plasma membrane. Biochem. J. 1994;299:303–308(Pt 1)
  36. Basse F, Gaffet P, Bienvenue A. Correlation between inhibition of cytoskeleton proteolysis and anti-vesiculation effect of calpeptin during A23187-induced activation of human platelets: Are vesicles shed by filopod fragmentation?. Biochim. Biophys. Acta. 1994;1190:217–224
  37. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor–positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102:2678–2683
  38. Simak J, Holada K, Risitano AM, et al. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 2004;125:804–813
  39. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science. 2002;296:1821–1825
  40. Bodin S, Tronchere H, Payrastre B. Lipid rafts are critical membrane domains in blood platelet activation processes. Biochim. Biophys. Acta. 2003;1610:247–257
  41. Jy W, Jimenez JJ, Mauro LM, et al. Agonist-induced capping of adhesion proteins and microparticle shedding in cultures of human renal microvascular endothelial cells. Endothelium. 2002;9:179–189
  42. Horejsi V. Lipid rafts and their roles in T-cell activation. Microbes Infect. 2005;7:310–316
  43. Mallat Z, Hugel B, Ohan J, et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348–353
  44. Aupeix K, Hugel B, Martin T, et al. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J. Clin. Invest. 1997;99:1546–1554
  45. Bernal-Mizrachi L, Jy W, Jimenez JJ, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am. Heart J. 2003;145:962–970
  46. Minagar A, Jy W, Jimenez JJ, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2001;56:1319–1324
  47. Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41:211–217
  48. Abid Hussein MN, Meesters EW, Osmanovic N, et al. Antigenic characterization of endothelial cell–derived microparticles and their detection ex vivo. J .Thromb. Haemost. 2003;1:2434–2443
  49. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95:930–935
  50. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000;101:841–843
  51. Berckmans RJ, Neiuwland R, Boing AN, et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb. Haemost. 2001;85:639–646
  52. Jimenez JJ, Jy W, Mauro LM, et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: Findings from brain and renal microvascular cell culture and patients with active disease. Br. J. Haematol. 2001;112:81–90
  53. Simak J, Holada K, D'Agnillo F, et al. Cellular prion protein is expressed on endothelial cells and is released during apoptosis on membrane microparticles found in human plasma. Transfusion. 2002;42:334–342
  54. Simak J, Gelderman MP, Yu H, et al. Elevated circulating endothelial microparticles in acute stroke patients: A correlation with brain lesion volume and outcome. Blood. 2004;104:954a;(abstract)
  55. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br. J. Haematol. 2003;123:896–902
  56. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 2003;197:1585–1598
  57. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer. 2005;92:305–311
  58. Ogura H, Tanaka H, Koh T, et al. Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. J. Trauma. 2004;56:823–830(discussion 830-821)
  59. Sabatier F, Roux V, Anfosso F, et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor–dependent procoagulant activity. Blood. 2002;99:3962–3970
  60. Brogan PA, Dillon MJ. Endothelial microparticles and the diagnosis of the vasculitides. Intern. Med. 2004;43:1115–1119
  61. Diamant M, Nieuwland R, Pablo RF, et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation. 2002;106:2442–2447
  62. Chou J, Mackman N, Merrill-Skoloff G, et al. Hematopoietic cell–derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004;104:3190–3197
  63. Aras O, Shet A, Bach RR, et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood. 2004;103:4545–4553
  64. Biro E, Sturk-Maquelin KN, Vogel GM, et al. Human cell–derived microparticles promote thrombus formation in vivo in a tissue factor–dependent manner. J .Thromb. Haemost. 2003;1:2561–2568
  65. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J. Immunol. 1994;153:3245–3255
  66. Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002;2:569–579
  67. Gilbert GE, Sims PJ, Wiedmer T, et al. Platelet-derived microparticles express high affinity receptors for factor VIII. J. Biol. Chem. 1991;266:17261–17268
  68. Hoffman M, Monroe DM, Roberts HR. Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: A flow cytometric study. Thromb. Haemost. 1992;68:74–78
  69. So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J .Thromb. Haemost. 2003;1:2510–2515
  70. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat. Med. 2003;9:458–462
  71. Butenas S, Bouchard BA, Brummel-Ziedins KE, et al. Tissue factor activity in whole blood. Blood. 2005;105:2764–2770
  72. Osterud B, Bjorklid E. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin. Scand. J. Haematol. 1982;29:175–184
  73. Egorina EM, Sovershaev MA, Bjorkoy G, et al. Intracellular and surface distribution of monocyte tissue factor: Application to intersubject variability. Arterioscler. Thromb. Vasc. Biol. 2005;25:1493–1498
  74. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb. Haemost. 2004;92:459–466
  75. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105:192–198
  76. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation. 1997;96:3534–3541
  77. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003;17:476–478
  78. Schecter AD, Spirn B, Rossikhina M, et al. Release of active tissue factor by human arterial smooth muscle cells. Circ. Res. 2000;87:126–132
  79. Brisset AC, Terrisse AD, Dupouy D, et al. Shedding of active tissue factor by aortic smooth muscle cells (SMCs) undergoing apoptosis. Thromb. Haemost. 2003;90:511–518
  80. Tans G, Rosing J, Thomassen MC, et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 1991;77:2641–2648
  81. Satta N, Freyssinet JM, Toti F. The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccharide. Br. J. Haematol. 1997;96:534–542
  82. Dahlback B, Wiedmer T, Sims PJ. Binding of anticoagulant vitamin K–dependent protein S to platelet-derived microparticles. Biochemistry. 1992;31:12769–12777
  83. Jy W, Mao WW, Horstman L, et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol. Dis. 1995;21:217–231(discussion 231a)
  84. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood. 2000;95:1317–1323
  85. Barry OP, Pratico D, Savani RC, et al. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J. Clin. Invest. 1998;102:136–144
  86. Barry OP, Pratico D, Lawson JA, et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J. Clin. Invest. 1997;99:2118–2127
  87. Barry OP, Kazanietz MG, Pratico D, et al. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2–dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase–dependent pathway. J. Biol. Chem. 1999;274:7545–7556
  88. Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension. 2004;43:428–433
  89. Iwamoto S, Kawasaki T, Kambayashi J, et al. Platelet microparticles: A carrier of platelet-activating factor?. Biochem. Biophys. Res. Commun. 1996;218:940–944
  90. Watanabe J, Marathe GK, Neilsen PO, et al. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J. Biol. Chem. 2003;278:33161–33168
  91. Mause SF, von Hundelshausen P, Zernecke A, et al. Platelet microparticles: A transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler. Thromb. Vasc. Biol. 2005;25:1512–1518
  92. Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J. Biol. Chem. 1999;274:23111–23118
  93. Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. Blood. 2004;104:2543–2548
  94. Gasser O, Schifferli JA. Microparticles released by human neutrophils adhere to erythrocytes in the presence of complement. Exp. Cell Res. 2005;307:381–387
  95. Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation. 2004;109:1653–1659
  96. Brodsky SV, Zhang F, Nasjletti A, et al. Endothelium-derived microparticles impair endothelial function in vitro. Am. J. Physiol. Heart Circ. Physiol. 2004;286:H1910–H1915
  97. Boulanger CM, Scoazec A, Ebrahimian T, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001;104:2649–2652
  98. Vanwijk MJ, Svedas E, Boer K, et al. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am. J. Obstet. Gynecol. 2002;187:1686–1693
  99. Kim HK, Song KS, Chung JH, et al. Platelet microparticles induce angiogenesis in vitro. Br. J. Haematol. 2004;124:376–384
  100. Brill A, Dashevsky O, Rivo J, et al. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc. Res. 2005;67:30–38
  101. Taraboletti G, D'Ascenzo S, Borsotti P, et al. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle–associated components by endothelial cells. Am. J. Pathol. 2002;160:673–680
  102. Mezentsev A, Merks RM, O'Riordan E, et al. Endothelial microparticles affect angiogenesis in vitro: The role of oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2005;289:H1106–H1114
  103. Janowska-Wieczorek A, Majka M, Kijowski J, et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood. 2001;98:3143–3149
  104. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer. 2005;113:752–760
  105. Fritzsching B, Schwer B, Kartenbeck J, et al. Release and intercellular transfer of cell surface CD81 via microparticles. J. Immunol. 2002;169:5531–5537
  106. Combes V, Coltel N, Alibert M, et al. ABCA1 gene deletion protects against cerebral malaria: Potential pathogenic role of microparticles in neuropathology. Am. J. Pathol. 2005;166:295–302
  107. Holada K, Simak J, Vostal JG. Transmission of BSE by blood transfusion. Lancet. 2000;356:1772
  108. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J. Gen. Virol. 2002;83:2897–2905
  109. Brown P, Cervenakova L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion. 1999;39:1169–1178
  110. Fevrier B, Raposo G. Exosomes: Endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 2004;16:415–421
  111. Fevrier B, Vilette D, Laude H, et al. Exosomes: A bubble ride for prions?. Traffic. 2005;6:10–17
  112. Bernal-Mizrachi L, Jy W, Fierro C, et al. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int. J. Cardiol. 2004;97:439–446
  113. Matsumoto N, Nomura S, Kamihata H, et al. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb. Haemost. 2004;91:146–154
  114. Ferreira AC, Peter AA, Mendez AJ, et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation. 2004;110:3599–3603
  115. Inami N, Nomura S, Takahashi N, et al. Correlation between platelet-derived microparticles and soluble L-selectin in patients undergoing hemodialysis. Thromb. Haemost. 2004;92:1452–1454
  116. Nomura S, Suzuki M, Katsura K, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995;116:235–240
  117. Omoto S, Nomura S, Shouzu A, et al. Detection of monocyte-derived microparticles in patients with type II diabetes mellitus. Diabetologia. 2002;45:550–555
  118. Morel O, Hugel B, Jesel L, et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb. Haemost. 2004;91:345–353
  119. Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002;51:2840–2845
  120. Kelton JG, Warkentin TE, Hayward CP, et al. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. Blood. 1992;80:2246–2251
  121. Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999;93:3451–3456
  122. Pihusch R, Hohnberg B, Salat C, et al. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 2002;81:454–461
  123. Pihusch R, Wegner H, Salat C, et al. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:381–387
  124. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999;353:1348–1353
  125. Bevers EM, Zwaal RF, Willems GM. The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin. Clin. Immunol. 2004;112:150–160
  126. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: A potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb. Haemost. 2004;91:667–673
  127. Nagahama M, Nomura S, Kanazawa S, et al. Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome. Autoimmunity. 2003;36:125–131
  128. Ambrozic A, Bozic B, Kveder T, et al. Budding, vesiculation and permeabilization of phospholipid membranes—evidence for a feasible physiologic role of beta2-glycoprotein I and pathogenic actions of anti–beta2-glycoprotein I antibodies. Biochim. Biophys. Acta. 2005;1740:38–44
  129. Kim HK, Song KS, Park YS, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. Eur J Cancer. 2003;39:184–191
  130. Kanazawa S, Nomura S, Kuwana M, et al. Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. Lung Cancer. 2003;39:145–149
  131. Joop K, Berckmans RJ, Nieuwland R, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb. Haemost. 2001;85:810–820
  132. Combes V, Taylor TE, Juhan-Vague I, et al. Circulating endothelial microparticles in Malawian children with severe falciparum malaria complicated with coma. JAMA. 2004;291:2542–2544
  133. Laude I, Rongieres-Bertrand C, Boyer-Neumann C, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: A new insight. Thromb. Haemost. 2001;85:18–21
  134. Bretelle F, Sabatier F, Desprez D, et al. Circulating microparticles: A marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb. Haemost. 2003;89:486–492
  135. VanWijk MJ, Nieuwland R, Boer K, et al. Microparticle subpopulations are increased in preeclampsia: Possible involvement in vascular dysfunction?. Am. J. Obstet. Gynecol. 2002;187:450–456
  136. Gonzalez-Quintero VH, Jimenez JJ, Jy W, et al. Elevated plasma endothelial microparticles in preeclampsia. Am. J. Obstet. Gynecol. 2003;189:589–593
  137. Gonzalez-Quintero VH, Smarkusky LP, Jimenez JJ, et al. Elevated plasma endothelial microparticles: Preeclampsia versus gestational hypertension. Am. J. Obstet. Gynecol. 2004;191:1418–1424
  138. Jimenez J, Jy W, Mauro LM, et al. Elevated endothelial microparticle–monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult. Scler. 2005;11:310–315
  139. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb. Res. 1993;72:295–304
  140. Knijff-Dutmer EA, Koerts J, Nieuwland R, et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002;46:1498–1503
  141. George JN, Pickett EB, Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood. 1986;68:307–309
  142. McGill M, Fugman DA, Vittorio N, et al. Platelet membrane vesicles reduced microvascular bleeding times in thrombocytopenic rabbits. J. Lab. Clin. Med. 1987;109:127–133
  143. Solberg C, Osterud B, Little C. Platelet storage lesion: Formation of platelet fragments with platelet factor 3 activity. Thromb. Res. 1987;48:559–565
  144. Divers SG, Kannan K, Stewart RM, et al. Quantitation of CD62, soluble CD62, and lysosome-associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates. Transfusion. 1995;35:292–297
  145. Wang C, Mody M, Herst R, et al. Flow cytometric analysis of platelet function in stored platelet concentrates. Transfus. Sci. 1999;20:129–139
  146. Devine DV, Bradley AJ, Maurer E, et al. Effects of prestorage white cell reduction on platelet aggregate formation and the activation state of platelets and plasma enzyme systems. Transfusion. 1999;39:724–734
  147. George JN, Pickett EB, Heinz R. Platelet membrane glycoprotein changes during the preparation and storage of platelet concentrates. Transfusion. 1988;28:123–126
  148. Gemmell CH. Flow cytometric evaluation of material-induced platelet and complement activation. J. Biomater. Sci. Polym. Ed. 2000;11:1197–1210
  149. Bode AP, Orton SM, Frye MJ, et al. Vesiculation of platelets during in vitro aging. Blood. 1991;77:887–895
  150. Bode AP, Knupp CL. Effect of cold storage on platelet glycoprotein Ib and vesiculation. Transfusion. 1994;34:690–696
  151. Gelderman MP, Carter LB, Simak J. High counts of potentially pathogenic cell membrane microparticles in apheresis platelets. Blood. 2004;104:988a
  152. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus. Med. Rev. 2003;17:120–162
  153. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499–1507
  154. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555–1562

 The views of the authors represent their scientific opinion and should not be construed as the opinion or policy of the US Food and Drug Administration.

PII: S0887-7963(05)00078-7

doi: 10.1016/j.tmrv.2005.08.001

Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 1-26 , January 2006

Article Tools

* Image Usage & Resolution